Cash from Operations (TTM) Chart

View Cash from Operations (TTM) for GLUE.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (TTM) Chart
Start Trial

Historical Cash from Operations (TTM) Data

View and export this data back to 2021. Start Trial.
Date Value
June 30, 2026 -24.07M
March 31, 2026 -14.68M
December 31, 2025 -22.80M
September 30, 2025 149.14M
June 30, 2025 27.72M
March 31, 2025 34.67M
December 31, 2024 42.00M
September 30, 2024 -57.29M
June 30, 2024 -61.00M
March 31, 2024 -58.56M
December 31, 2023 -43.80M
Date Value
September 30, 2023 -97.40M
June 30, 2023 -93.29M
March 31, 2023 -88.47M
December 31, 2022 -92.47M
September 30, 2022 -82.68M
June 30, 2022 -79.87M
March 31, 2022 -72.95M
December 31, 2021 -59.36M
September 30, 2021 -53.76M
June 30, 2021 -42.86M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (TTM) Range, Past 5 Years

View Cash from Operations (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (TTM) Benchmarks

View Cash from Operations (TTM) Benchmarks
Start Trial
Nurix Therapeutics, Inc. -293.70M
Gilead Sciences, Inc. 13.55B
Ironwood Pharmaceuticals, Inc. 185.56M
Capricor Therapeutics, Inc. -104.00M
Cue Biopharma, Inc. -50.05M